M. Puoti

Hepatology · 2008–2020

A researcher in the Science corpus: 6 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom M. Puoti trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Lavanchy (in Hepatology)

Papers from M. Puoti's perspective

Ordered by how strongly the researchers M. Puoti trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. (New England Journal of Medicine)
  2. Sofosbuvir for previously untreated chronic hepatitis C infection. (New England Journal of Medicine)
  3. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (New England Journal of Medicine)
  4. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (New England Journal of Medicine)
  5. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive… (The Lancet)
  6. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (New England Journal of Medicine)
  7. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination… (The Lancet)
  8. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. (Journal of Clinical Epidemiology)
  9. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”? (Hepatology)
  10. Telaprevir for retreatment of HCV infection. (New England Journal of Medicine)

Their papers